Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

Abstract Background No chemotherapeutic agents have been standardised for transarterial chemoembolisation (TACE). In particular, doxorubicin has no defined optimal dosage in TACE procedures. We compared low versus currently used dose of doxorubicin for TACE in patients with hepatocellular carcinoma...

Full description

Bibliographic Details
Main Authors: Ahmed A. Bessar, Ahmed Farag, Sameh M. Abdel Monem, Fady M. Wadea, Shady E. Shaker, Mahmoud Ahmed Ebada, Manar A. Bessar
Format: Article
Language:English
Published: SpringerOpen 2021-03-01
Series:European Radiology Experimental
Subjects:
Chemoembolization (therapeutic)
Doxorubicin
Carcinoma (hepatocellular)
Hepatitis
Online Access:https://doi.org/10.1186/s41747-021-00204-6

Internet

https://doi.org/10.1186/s41747-021-00204-6

Similar Items